Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality

BWC Tse; M Volpert; E Ratther; N Stylianou; M Nouri; K McGowan; ML Lehman; SJ McPherson; M Roshan-Moniri; MS Butler; J Caradec; CY Gregory-Evans; J McGovern; R Das; M Takhar; N Erho; M Alshalafa; E Davicioni; EM Schaeffer; RB Jenkins; AE Ross; RJ Karnes; RB Den; L Fazli; PA Gregory; ME Gleave; ED Williams; PS Rennie; R Buttyan; JH Gunter; LA Selth; PJ Russell; CC Nelson; BG Hollier

Journal article

Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality

BWC Tse, M Volpert, E Ratther, N Stylianou, M Nouri, K McGowan, ML Lehman, SJ McPherson, M Roshan-Moniri, MS Butler, J Caradec, CY Gregory-Evans, J McGovern, R Das, M Takhar, N Erho, M Alshalafa, E Davicioni, EM Schaeffer, RB Jenkins Show all

Oncogene | NATURE PUBLISHING GROUP | Published : 2017

DOI: 10.1038/onc.2016.482

University of Melbourne Researchers

Elizabeth Williams Author Surgery - St Vincent's Hospital

Grants

Awarded by Cancer Australia PdCCRS grant

Funding Acknowledgements

We thank Dr Leland Chung and Dr Simon Hayward for kindly providing the C4-2B and BPH-1 cell lines, respectively, used in this study. This research was supported by Cure Cancer Australia Foundation, Prostate Cancer Foundation of Australia and Cancer Australia PdCCRS grant 108878 and the Australian Government Department of Health, Queensland Government National and International Research Alliance Program funding to the Australian-Canadian Prostate Cancer Research Alliance, as well as by the Movember Foundation and the Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award.